Key Points
- Teladoc CEO Charles Divita III sold 17,138 shares on Dec. 11 at an average price of $7.63 for $130,762.94, cutting his position by 7.86% to 201,036 shares (about $1.53M).
- Teladoc trades near $7.63 (52‑week range $6.35–$15.21) with a market cap ≈$1.35B, negative profitability (PE -5.96, negative net margin), reported Q3 EPS of -$0.21 (beat estimates) and set Q4 2025 guidance of -0.25 to -0.10.
- Institutional investors own about 76.82% of the stock and analyst coverage is mixed—five Buys, twelve Holds, one Sell—with an average rating of Hold and an average price target of $9.60.
Teladoc Health, Inc. (NYSE:TDOC - Get Free Report) CEO Charles Divita III sold 17,138 shares of the firm's stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $7.63, for a total value of $130,762.94. Following the completion of the transaction, the chief executive officer owned 201,036 shares of the company's stock, valued at $1,533,904.68. This trade represents a 7.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Teladoc Health Stock Up 0.1%
Teladoc Health stock opened at $7.63 on Friday. The business's 50-day simple moving average is $7.97 and its two-hundred day simple moving average is $7.78. The company has a debt-to-equity ratio of 0.71, a quick ratio of 2.60 and a current ratio of 2.70. The company has a market cap of $1.35 billion, a PE ratio of -5.96 and a beta of 2.04. Teladoc Health, Inc. has a fifty-two week low of $6.35 and a fifty-two week high of $15.21.
Teladoc Health (NYSE:TDOC - Get Free Report) last announced its quarterly earnings data on Wednesday, October 29th. The health services provider reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.05. Teladoc Health had a negative return on equity of 10.59% and a negative net margin of 8.84%.The firm had revenue of $626.44 million during the quarter, compared to analysts' expectations of $625.66 million. During the same period last year, the business posted ($0.19) earnings per share. The company's revenue for the quarter was down 2.2% compared to the same quarter last year. Teladoc Health has set its Q4 2025 guidance at -0.250--0.100 EPS. Equities analysts anticipate that Teladoc Health, Inc. will post -1.16 EPS for the current year.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of TDOC. Vanguard Group Inc. grew its stake in Teladoc Health by 7.0% in the 1st quarter. Vanguard Group Inc. now owns 19,752,338 shares of the health services provider's stock valued at $157,229,000 after acquiring an additional 1,289,183 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Teladoc Health by 5.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,571,673 shares of the health services provider's stock valued at $20,471,000 after acquiring an additional 127,960 shares during the last quarter. National Bank of Canada FI lifted its stake in Teladoc Health by 79.4% in the 1st quarter. National Bank of Canada FI now owns 3,571 shares of the health services provider's stock worth $28,000 after purchasing an additional 1,581 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Teladoc Health during the 1st quarter worth approximately $252,000. Finally, Nuveen LLC purchased a new stake in shares of Teladoc Health in the first quarter valued at approximately $11,789,000. Institutional investors and hedge funds own 76.82% of the company's stock.
Analyst Ratings Changes
TDOC has been the subject of several research reports. Zacks Research cut shares of Teladoc Health from a "strong-buy" rating to a "hold" rating in a research note on Monday, November 10th. Weiss Ratings restated a "sell (e+)" rating on shares of Teladoc Health in a research report on Monday. Evercore ISI cut their price target on Teladoc Health from $9.00 to $8.00 and set an "in-line" rating on the stock in a research report on Thursday, October 30th. Citigroup boosted their price objective on Teladoc Health from $9.50 to $10.50 and gave the company a "neutral" rating in a report on Tuesday, October 21st. Finally, Barclays assumed coverage on Teladoc Health in a research note on Tuesday. They issued an "equal weight" rating and a $8.50 target price on the stock. Five investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $9.60.
Get Our Latest Report on Teladoc Health
About Teladoc Health
(
Get Free Report)
Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
